Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1900+0.0300 (+2.59%)
At close: 04:00PM EST
1.2300 +0.04 (+3.36%)
After hours: 05:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.1600
Open1.1600
Bid1.1800 x 1800
Ask1.1900 x 900
Day's range1.1500 - 1.2500
52-week range1.1000 - 8.8100
Volume447,695
Avg. volume682,677
Market cap132.041M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-0.6700
Earnings date08 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.33
  • Business Wire

    Precision BioSciences Announces Change to its Board of Directors

    DURHAM, N.C., November 10, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.

  • Zacks

    Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

    Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

    DURHAM, N.C., November 08, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.